Skip to main content

Table 5 Best Response Rates by cohort.

From: Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer

Cohort Progressive Disease Stable Disease Partial Response Complete Response
1 3 0 0 0
2 2 1 0 0
3 1 2 0 0
4 5 1 0 0
5 2 0 1 0
\